Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2021-03-03 Report Publication Anno…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Investor Presentation
Report Publication Announcement Classification · 99% confidence The document explicitly states in the title section: "Investor Presentation". It further details that the company "announces that it will provide a live presentation on Tuesday 9 March 2021 at 4.00pm covering the recent £25m fundraise and Open Offer..." This content directly matches the definition of an Investor Presentation (IP), which focuses on presenting strategy and financials to investors, often scheduled around corporate events like fundraising. Although it is an announcement of a presentation, the core subject matter is the presentation itself, making IP a stronger fit than RPA or RNS, especially given the detailed description of the content to be presented.
2021-03-03 English
Publication of Circular and Notice of GM
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an RNS announcement from Shield Therapeutics PLC, dated March 1, 2021. The title explicitly states 'Publication of Circular and Notice of General Meeting'. It details the terms of an Open Offer contingent on a prior Placing/Subscription, and provides a detailed timetable leading up to a General Meeting on March 18, 2021. The core purpose is to announce the publication of the Circular and the Notice of Meeting, which solicits shareholder votes (via proxy) for resolutions related to the fundraising. This content strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), as it provides necessary information and procedures for shareholders to vote on corporate actions (the fundraising resolutions). While it announces a Circular, the content itself is the solicitation/information required for the upcoming vote, making PSI the most specific fit over a general RPA or RNS.
2021-03-01 English
Successful completion of £25 million Fundraise
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement (RNS Number: 5701Q) dated February 26, 2021, detailing the 'Successful completion of £25 million Fundraise' via a placing and subscription, and announcing an upcoming Open Offer conditional on a General Meeting. This clearly describes a corporate financing activity involving the issuance of new shares to raise capital. This aligns directly with the definition of 'Capital/Financing Update' (Code: CAP). Although it is an RNS announcement, the core content is the financing event itself, not just a notice that a report is available (which would suggest RPA or RNS). Since 'CAP' is a specific category for fundraising, it takes precedence over the general 'RNS' fallback.
2021-02-26 English
Total Voting Rights Update
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number : 5017Q' and contains a 'Total Voting Rights Update'. It explicitly states the total number of issued shares and confirms this figure is used for shareholder notification calculations under FCA rules. This type of mandatory disclosure regarding the total number of voting rights is a standard regulatory announcement. While it relates to share capital, it is not a formal share issue/change (SHA) or a transaction in own shares (POS), but rather a periodic regulatory update required by the FCA. Since it is a specific regulatory announcement that doesn't fit the other precise categories (like DIV, DIRS, ER, etc.), and it is distributed via RNS, it falls best under the general Regulatory Filings category (RNS) or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). Given the content is purely about the denominator for voting rights notification, DVA is a strong candidate, but RNS is the broader regulatory filing category used for such mandatory updates distributed via the London Stock Exchange's service. However, looking closely at the definitions, DVA is for 'Official results from shareholder votes at any general meeting'. This is not a result of a vote, but a statement of the total share count for voting purposes. Therefore, the most appropriate general regulatory category is RNS, as it is a standard, required regulatory update distributed through the RNS system.
2021-02-26 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1941 characters) and contains the header 'RNS Number : 5121Q'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of brief, immediate market operational announcement, especially one explicitly labeled with an RNS number and distributed by the LSE's news service, fits best under the general Regulatory Filings category, as it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, SHA, DIRS). It is a miscellaneous regulatory notice.
2021-02-26 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1924 characters) and contains the header 'RNS Number : 5096Q'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the appropriate fallback category is Regulatory Filings (RNS).
2021-02-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.